Debiopharm Group and MSM Protein Technologies have announced the signature of an exclusive agreement for the development and commercialization of Debio 0929, an antibody targeting a G-protein-coupled receptor (GPCR) to be developed into a new oncology therapeutic drug.
30 July, 2009
Axel Ullrich, PhD, director of the Department of Molecular Biology at the Max Planck Institute of Biochemistry in Germany, whose discoveries have led to novel cancer therapies including Herceptin® (trastuzumab), has been announced as the winner of the 2009 Dr Paul Janssen Award for Biomedical Research.
30 July, 2009
MorphoSys and the University of Melbourne have recently announced an agreement to cooperate on investigating new therapeutic applications for MorphoSys’s MOR103 program.
29 July, 2009
Amgen and GlaxoSmithKline recently announced a collaboration in which the companies will share commercialization of Amgen’s monoclonal antibody denosumab for postmenopausal osteoporosis in Europe, Australia, New Zealand and Mexico once the product is approved in these countries.
28 July, 2009
Roche and Google.org have recently started a joint project to demonstrate the feasibility of developing a multidisciplinary surveillance, research and response system. This system will enhance the ability to predict and prevent emerging infectious diseases in East Africa.
28 July, 2009
Cancer Research Technology, Merck Serono, Cancer Research UK, Cardiff University and The Institute of Cancer Research are set to begin a new research collaboration that will provide substantial investment in research on the WNT signalling pathway in the hope of finding new drug targets.
27 July, 2009
The pharmaceutical sector is set to get its own body dedicated to identifying and addressing key skills issues.
23 July, 2009
Ontario is joining forces with Pfizer Inc. and leading Ontario research institutions to develop a new generation of drugs to fight colorectal cancer.
23 July, 2009